Dual chain synthetic heparin-binding growth factor analogs

Details Dual chain synthetic heparin-binding growth factor analogs Dual chain synthetic heparin-binding growth factor analogs

2005-02-24

2009-10-06

Landsman, Robert (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S056000, C530S300000, C530S397000, C530S399000, C530S402000

Reexamination Certificate

active

07598224

ABSTRACT:
The invention provides synthetic heparin-binding growth factor analogs having two peptide chains each branched from a branch moiety, such as trifunctional amino acid residues, the branch moieties separated by a first linker of from 3 to about 20 backbone atoms, which peptide chains bind a heparin-binding growth factor receptor and are covalently bound to a non-signaling peptide that includes a heparin-binding domain, preferably by a second linker, which may be a hydrophobic second linker. The synthetic heparin-binding growth factor analogs are useful as pharmaceutical agents, soluble biologics or as surface coatings for medical devices.

REFERENCES:
patent: 4172128 (1979-10-01), Thiele et al.
patent: 4563350 (1986-01-01), Nathan et al.
patent: 5563046 (1996-10-01), Mascarenhas et al.
patent: 5608035 (1997-03-01), Yanofsky et al.
patent: 5635597 (1997-06-01), Barrett et al.
patent: 5643873 (1997-07-01), Barrett et al.
patent: 5648458 (1997-07-01), Cwirla et al.
patent: 5654276 (1997-08-01), Barrett et al.
patent: 5668110 (1997-09-01), Barrett et al.
patent: 5674977 (1997-10-01), Gariepy
patent: 5679637 (1997-10-01), Lappi et al.
patent: 5679673 (1997-10-01), Bowen et al.
patent: 5684136 (1997-11-01), Godowski
patent: 5728802 (1998-03-01), Barrett et al.
patent: 5759515 (1998-06-01), Rhodes et al.
patent: 5767234 (1998-06-01), Yanofsky et al.
patent: 5770704 (1998-06-01), Godowski
patent: 5773569 (1998-06-01), Wrighton et al.
patent: 5786322 (1998-07-01), Barrett et al.
patent: 5786331 (1998-07-01), Barrett et al.
patent: 5789182 (1998-08-01), Yayon et al.
patent: 5830851 (1998-11-01), Wrighton et al.
patent: 5861476 (1999-01-01), Barrett et al.
patent: 5866113 (1999-02-01), Hendriks et al.
patent: 5869451 (1999-02-01), Dower et al.
patent: 5880096 (1999-03-01), Barrett et al.
patent: 5902799 (1999-05-01), Herrmann et al.
patent: 5932462 (1999-08-01), Harris et al.
patent: 5952474 (1999-09-01), Kayman et al.
patent: 5955588 (1999-09-01), Tsang et al.
patent: 5965532 (1999-10-01), Bachovchin
patent: 5989866 (1999-11-01), Deisher et al.
patent: 5994104 (1999-11-01), Anderson et al.
patent: 6001364 (1999-12-01), Rose et al.
patent: 6011002 (2000-01-01), Pastan et al.
patent: 6030812 (2000-02-01), Bauer et al.
patent: 6051648 (2000-04-01), Rhee et al.
patent: 6121236 (2000-09-01), Ben-Sasson
patent: 6168784 (2001-01-01), Offord et al.
patent: 6174530 (2001-01-01), Rose et al.
patent: 6174721 (2001-01-01), Innis et al.
patent: 6214795 (2001-04-01), Benjamin et al.
patent: 6217873 (2001-04-01), Rose et al.
patent: 6235716 (2001-05-01), Ben-Sasson
patent: 6251864 (2001-06-01), Dower et al.
patent: 6284503 (2001-09-01), Caldwell et al.
patent: 6294359 (2001-09-01), Fiddes et al.
patent: 6323323 (2001-11-01), Sledziewski et al.
patent: 6326468 (2001-12-01), Canne et al.
patent: 6342591 (2002-01-01), Zamora et al.
patent: 6350731 (2002-02-01), Jehanli et al.
patent: 6377349 (2002-04-01), Fercher
patent: 6451543 (2002-09-01), Kochendoerfer et al.
patent: 2003/0224996 (2003-12-01), Opperman et al.
patent: WO-00/18921 (2000-04-01), None
patent: WO-02/04015 (2002-01-01), None
patent: WO-02/20033 (2002-03-01), None
patent: WO-0219963 (2002-03-01), None
patent: WO-02/062823 (2002-08-01), None
Bork et al., Go hunting in sequence databases but watch out for the traps, 1996, Trends in Genetics, vol. 12, pp. 425-427.
Bork, Powers and Pitfalls in Sequence Analysis: the 70% hurdle, 2000, Genome Research, vol. 10, pp. 398-400.
Brenner, Errors in genome annotation, 1999, Trends in Genetics, vol. 15, pp. 132-132.
Doerks et al., Protein annotation: detective work for function prediction, 1998, Trends in Genetics, vol. 14, pp. 248-250.
Ngo et al., The protein folding problem and tertiary structure prediction,1994, pp. 492-495.
Skolnick et al., From genes to protein structure and function: novel applications of computational approaches in the genomic era, 2000, Trends in Biotech, vol. 18, Issue 1, pp. 34-39.
Smith et al., The challenge of genome sequence annotation or “the devil is in the details”, 1997, Nature Biotechnology, vol. 15, pp. 1222-1223.
Wells et al., Addivity of mutational effects in proteins, 1990, Biochemistry, vol. 29, pp. 8509-8517.
Ahmed, Asif, et al., “Role of VEFGF Receptor-1 (Fit-1) in Mediating Calcium-Dependent Nitric Oxide Release and Limiting DNA Synthesis in Human Trophoblast Cells”,Lab Invest., vol. 76(6), (Jun. 1977),779-791.
Andrades, Jose A., et al., “A Recombinant Human TGF-B1 Fusion Protein with Collagen-Binding Domain Promostes Migration, Growth, and Differentiation of Bone Marrow Mesenchymal Cells”,Experimental Cell Research, (1999),485-498.
Ballinger, Marcus D., et al., “Semirational design of a potent, artificial agonist of fibroblast growth factor receptors”,Nature Biotechnology, (1999),1199-1204.
Binetruy-Tournaire, Roselyne, et al., “Identification of a Peptide Blocking Vascular Endothelial Growth Factor (VEGF)-mediated Angiogenesis”,The EMBO Journal, vol. 19, No. 7, (2000),1525-1533.
Brennand, David M., et al., “Identification of a Cyclic Peptide Inhibitor of Platelet-Derived Growth Factor-BB Receptor-Binding and Mitogen-Induced DNA Synthesis in Human Fibroblasts”,FEBS Letters, 413, (1997),70-74.
Carmeliet, Peter, et al., “Growing Better Blood Vessels” ,Nature Biotechnology, (2001),1019-1020.
Dawson, Philip E., et al., “Synthesis of Native Proteins by Chemical Ligation”,Annu. Rev. Biochem, 2000, 69, (2000),923-960.
Dikov, Michael M., et al., “A Functional Fibroblast Growth Factor-1 Immunoglobulin Fusion Protein”,The Journal of Biological Chemistry, (1998),15811-15817.
Engstrom, Ulla, et al., “Identification of a Peptide Antagonist for Platelet-Derived Growth Factor”,The Journal of Biological Chemistry, vol. 273, No. 25, (1998),15811-15817.
Eom, Khee D., et al., “Tandem Ligation of Multipartite Peptides with Cell-Permeable Activity”,J. Am. Chem. Soc., 2003,125, (2003),73-83.
Gay, Cyril G., et al., “Interleukin 1 regulated heparin-binding growth factor 2 gene expression in vascular smooth muscle cells”,Proc. Natl. Acad. Sci. USA, vol. 88, (Jan. 1991),296-300.
Hasan, Maemunah, et al., “IL-12 is a Heparin-Binding Cytokine”,The Journal of Immunology, (1999), 1064-1070.
Hoke, David E., et al., “A Heparin Binding Synthetic Peptide from Human HIP/RPL29 Fails to Specifically Differentiate Between Anticoagulantly Active and Inactive Species of Heparin”,Journal of Negative Results in BioMedicine, (2003).
Kochendoefer, Gerd, et al., “Design and Chemical Synthesis of Homogenous Polymer-Modified Erythropotesis Protein”,Science, vol. 299, (Feb. 7, 2003).
Ostman, Arne, et al., “Identification of Three Amino Acids in the Platelet-Derived Growth Factor (PDGF) B-chain that are Important for Binding to the PDGF B-Receptor”,The Journal of Biological Chemistry, vol. 266, No. 16, Issue of Jun. 5, (1991),10073-10077.
Paris, Francois, et al., “Endothelial Apoptosis as the Primary Lesion Initiating Intestinal Radiation Damage in Mice”,Science, (2001),293-297.
Pellegrini, Luca, “Role of heparan sulfate in fibroblast growth factor signaling a structural view”,Structural Biology, (2001),629-634.
Ray, Jasohara, et al., “A 10-amino acid sequence of fibroblast growth factor 2 is sufficient for its mitogenic activity on neural progenitor cells”,Proc. Natl. Acad. Sci. USA, (1997),7047-7052.
Richardson, Thomas P., et al., “Polymeric system for dual growth factor delivery”,Nature Biotechnology, (2001),293-297.
Rusnati, Marco, et al., “avB3 Integrin Mediates the Cell-adhesive Capacity and Biological Activity of Basic Fibroblast Growth Factor (FGF-2) in Cultured Endothelial Cells”,Molecular Biology of the Cell, (1997),2449-2461.
Sood, R., et al., “MDS1/EVI1 enhances TGF-B1 signaling and strengthens its growth-inhibitory effect, but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3:21),

Affiliated with

Also associated with

Rating

Dual chain synthetic heparin-binding growth factor analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dual chain synthetic heparin-binding growth factor analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dual chain synthetic heparin-binding growth factor analogs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4115790